Insider Selling Activity at Applied Therapeutics, Inc.

Applied Therapeutics, Inc. (NASDAQ: APLT) has seen an insider sell shares of its stock. On Thursday, February 6th, Leslie D. Funtleyder, an insider of the company, sold 22,950 shares. This transaction was completed at an average price of $0.61 per share, resulting in a total sale value of $13,999.50. Following this sale, Funtleyder now directly holds 404,961 shares of Applied Therapeutics, with a total estimated value of about $247,026.21. It is significant to note that this sale represents a 5.36 percent decrease in Funtleyder's ownership stake in the company. The details of the transaction have been reported in a filing with the SEC and can be reviewed through their official site.

Current Performance of Applied Therapeutics Stock

During midday trading on Friday, the shares of Applied Therapeutics maintained a price of $0.61. Trading activity showed that 1,845,842 shares moved hands, which is lower than the average trading volume of approximately 5,416,228 shares. The company's fifty-day moving average price is reported at $0.90, while the 200-day moving average stands at $5.14. With a market capitalization of around $70.99 million, Applied Therapeutics' price-to-earnings ratio is negative at -0.38, indicating potential challenges in profitability. The stock has experienced a twelve-month low of $0.54 and a high of $10.62.

Analyst Perspectives and Revised Price Targets

In recent evaluations, various research analysts have shared their insights regarding the shares of Applied Therapeutics. UBS Group reiterated a "neutral" rating while lowering the target price to $2.00 from $13.00. Similarly, Robert W. Baird reduced their rating from $14.00 to a target of $5.00 while maintaining an "outperform" stance on the stock. Citigroup has also lowered their price objective from $13.00 to $8.00 and confirmed a "buy" recommendation. Furthermore, William Blair downgraded their recommendation from "outperform" to "market perform" in December. Additionally, Royal Bank of Canada revised down their price target on APLT shares from $4.00 to $1.50, assigning a "sector perform" rating. Overall, analysts have rated the stock as a moderate buy, with a consensus price target averaging $6.10.

Institutional Investor Activity

In light of recent market fluctuations, several hedge funds and other institutional investors have altered their positions in Applied Therapeutics. SG Americas Securities LLC significantly increased its stake by 169.0% in the fourth quarter, acquiring 40,747 shares valued at approximately $35,000. The Private Advisor Group also entered a new investment during the fourth quarter with a similar valuation. Other entities like Algert Global LLC and Y Intercept Hong Kong Ltd have acquired new positions in the company, indicating growing interest from institutional investors, who now own approximately 98.31% of the company's shares.

About Applied Therapeutics

Applied Therapeutics, Inc. is a clinical-stage biopharmaceutical company focused on developing a range of product candidates aimed at significant medical needs. Their leading candidate, AT-007 (also known as govorestat), has successfully completed phase 3 trials for the treatment of galactosemia among both adult and pediatric groups.

Insider, Selling, Stock